Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.matbio.2014.01.015 http://scihub22266oqcxt.onion/10.1016/j.matbio.2014.01.015 C4039577!4039577 !24513039     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24513039 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24513039 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Matrix+Biol 2014 ; 35 (ä): 152-61 Nephropedia Template TP {{tp|p=24513039 |t=2014. Versican and the control of inflammation |pdf=|usr=}}{{24513039 }} gab.com Text Versican and the control of inflammation JO: Matrix Biol http://www.kidney.de/pget.php?&tw=1&pmid=24513039 #FOAvip Versican is an extracellular matrix (ECM) proteoglycan that interacts with cells by binding to non-integrin and integrin receptors and to other ECM components that associate with the cell surface. Recent studies have shown also that versican interacts with myeloid and lymphoid cells promoting their adhesion and production of inflammatory cytokines. Versican is produced by stromal cells, as well as leukocytes, and is markedly increased in inflammation. Inflammatory agonists, such as double-stranded RNA mimetics (e.g., poly I:C), stimulate stromal cells, smooth muscle cells and fibroblasts, to produce fibrillar ECMs enriched in versican and hyaluronan (HA) that interact with leukocytes promoting their adhesion. Interference with the incorporation of versican into this ECM blocks monocyte adhesion and dampens the inflammatory response. Tumor cells also express elevated levels of versican which interact with myeloid cells to promote an inflammatory response, through stimulating cytokine release, and metastasis. In addition, myeloid cells, such as macrophages in tumors, synthesize versican which affects tumor cell phenotypes, inflammation, and subsequent metastasis. Versican, by binding to hyaluronan, influences T lymphocyte phenotypes and in part controls the ability of these cells to synthesize and secrete cytokines that influence the immune response. Collectively, these studies indicate that versican as an ECM molecule plays a central role in inflammation and as a result it is emerging as a potential target promising wide therapeutic benefits. Twit Text FOAVip Versican and the control of inflammation ????Matrix Biol http://www.kidney.de/pget.php?&tw=1&pmid=24513039 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24513039 #FOAvip English Wikipedia <ref>{{Cite pmid|24513039 }}</ref> Versican and the control of inflammation #MMPMID24513039 Wight TN ; Kang I ; Merrilees MJ Matrix Biol 2014[Apr]; 35 (ä): 152-61 PMID24513039 show ga Versican is an extracellular matrix (ECM) proteoglycan that interacts with cells by binding to non-integrin and integrin receptors and to other ECM components that associate with the cell surface. Recent studies have shown also that versican interacts with myeloid and lymphoid cells promoting their adhesion and production of inflammatory cytokines. Versican is produced by stromal cells, as well as leukocytes, and is markedly increased in inflammation. Inflammatory agonists, such as double-stranded RNA mimetics (e.g., poly I:C), stimulate stromal cells, smooth muscle cells and fibroblasts, to produce fibrillar ECMs enriched in versican and hyaluronan (HA) that interact with leukocytes promoting their adhesion. Interference with the incorporation of versican into this ECM blocks monocyte adhesion and dampens the inflammatory response. Tumor cells also express elevated levels of versican which interact with myeloid cells to promote an inflammatory response, through stimulating cytokine release, and metastasis. In addition, myeloid cells, such as macrophages in tumors, synthesize versican which affects tumor cell phenotypes, inflammation, and subsequent metastasis. Versican, by binding to hyaluronan, influences T lymphocyte phenotypes and in part controls the ability of these cells to synthesize and secrete cytokines that influence the immune response. Collectively, these studies indicate that versican as an ECM molecule plays a central role in inflammation and as a result it is emerging as a potential target promising wide therapeutic benefits. |*Models, Biological [MESH] |Animals [MESH] |Cell Adhesion/*physiology [MESH] |Extracellular Matrix/*metabolism [MESH] |Genetic Vectors [MESH] |Humans [MESH] |Inflammation/metabolism/*prevention & control [MESH] |Lymphocyte Activation/*immunology [MESH] |Lymphocytes/metabolism [MESH] |Mice [MESH] |Molecular Structure [MESH] |Myeloid Cells/metabolism [MESH] |Protein Isoforms/genetics/metabolism [MESH] |Retroviridae [MESH] |T-Lymphocytes/physiology [MESH] |Transduction, Genetic [MESH]Versican and the control of inflammation (epmc).pdf DeepDyve Pubget Overpricing